The National Institute for Health and Care Excellence (“NICE”) has selected Speedboat Inject to be scoped and routed for guidance in respect of the endoscopic submucosal dissection (“ESD”) of lower gastrointestinal (“GI”) lesions.
This selection follows a committee review of headline data and initiates a multi-step process whereby Speedboat’s lower GI ESD clinical and economic evidence, along with other data, is evaluated by NICE and, if appropriate, may result in a specific NICE output such as Medical Technologies Guidance.
NICE selected Speedboat Inject for scoping and routing because it “anticipate[s] the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources”.
More information on Speedboat’s guidance development can be found here.
Craig Gulliford, CEO of Creo Medical, said:
We are delighted that Speedboat Inject has reached this stage with NICE and the validation this provides given the progress we are already making in the UK. We look forward to the outcome of the final stages of the review process as NICE concludes its work.
For press enquiries please contact media@creomedical.com. For all other enquiries please visit our Contact page.